Philippe Devillier
Overview
Explore the profile of Philippe Devillier including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
149
Citations
1786
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Zielen S, Richter H, Zieglmayer P, Gerstlauer M, Cognet-Sice J, Scurati S, et al.
Allergol Int
. 2025 Mar;
PMID: 40059026
Background: Patients with allergic rhinitis (AR) and/or mild or moderate asthma derived from birch-family pollen allergy can be treated with liquid sublingual immunotherapy (SLIT-liquid). This study evaluated the impact of...
2.
Sousa-Pinto B, Costa E, Vieira R, Klimek L, Czarlewski W, Pfaar O, et al.
Clin Exp Allergy
. 2025 Feb;
55(3):226-238.
PMID: 39956639
Background: Adherence to rhinitis treatment has been insufficiently assessed. We aimed to use data from the MASK-air mHealth app to assess adherence to oral antihistamines (OAH), intra-nasal corticosteroids (INCS) or...
3.
Bardin E, Hunzinger N, Lamy E, Roquencourt C, Zhou B, Tabache Y, et al.
J Cyst Fibros
. 2025 Jan;
PMID: 39843342
Background: The triple combination Elexacaftor/Tezacaftor/Ivacaftor (ETI) translates into major respiratory improvements in adults; yet current clinical endpoints may prove insufficiently sensitive in young children. We hypothesised that ETI rapidly modifies...
4.
Mottet G, Grassart A, Barthelemy P, Antignac C, Arrabal S, Bourdin A, et al.
Therapie
. 2025 Jan;
80(1):17-31.
PMID: 39809611
Over the past decade, new in vitro biological models have emerged which can reproduce certain characteristics of human physiology and pathologies. From organoids to organs-on-chips, these new technologies are currently...
5.
Mottet G, Grassart A, Barthelemy P, Antignac C, Arrabal S, Bourdin A, et al.
Therapie
. 2024 Dec;
80(1):1-16.
PMID: 39710544
No abstract available.
6.
Demoly P, Molimard M, Bergmann J, Delaisi B, Gouverneur A, Vadel J, et al.
Lancet Reg Health Eur
. 2024 Nov;
46:101120.
PMID: 39498359
[This corrects the article DOI: 10.1016/j.lanepe.2024.100915.].
7.
Bousquet J, Sousa-Pinto B, Anto J, Bedbrook A, Czarlewski W, Ansotegui I, et al.
Clin Transl Allergy
. 2024 Sep;
14(9):e12390.
PMID: 39313483
Patient-reported outcome measures (PROMs) are used to assess a patient's health status at a particular point in time. They are essential in the development of person-centred care. This paper reviews...
8.
Lamy E, Roquencourt C, Zhou B, Salvator H, Moine P, Annane D, et al.
Anal Bioanal Chem
. 2024 Jul;
416(22):4929-4939.
PMID: 38980330
Exhaled breath volatilomics is a powerful non-invasive tool for biomarker discovery in medical applications, but compound annotation is essential for pathophysiological insights and technology transfer. This study was aimed at...
9.
Bousquet J, Schunemann H, Sousa-Pinto B, Zuberbier T, Togias A, Samolinski B, et al.
J Allergy Clin Immunol Pract
. 2024 Jul;
12(10):2648-2668.e2.
PMID: 38971567
The traditional healthcare model is focused on diseases (medicine and natural science) and does not acknowledge patients' resources and abilities to be experts in their own lives based on their...
10.
Demoly P, Molimard M, Bergmann J, Delaisi B, Gouverneur A, Vadel J, et al.
Lancet Reg Health Eur
. 2024 May;
41:100915.
PMID: 38707866
Background: The only disease-modifying treatment currently available for allergic rhinitis (AR) is allergen immunotherapy (AIT). The main objective of the EfficAPSI real-world study (RWS) was to evaluate the impact of...